Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Oncology
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)?
There are 1 clinical trial targeting Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) tracked by BioSniper.
What is the prevalence of Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)?
The estimated prevalence of Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) is approximately 256.0 per 100,000 population.
Deep-dive into Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis